Alnylam Pharmaceuticals Inc

ALNY

$147.50

-16.2% last 12 months

Stanley Druckenmiller Holding value: $9.43 Million Ken Griffin Holding value: $311 Thousand Joel Greenblatt Holding value: $191 Thousand Steven Cohen Holding value: $0 Julian Robertson Holding value: $0 Jim Simons Holding value: $0 Tom Russo Holding value: $0 Cathie Wood Holding value: $0 Ray Dalio Holding value: $0 George Soros Holding value: $0

Market Cap

$17.7 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$117.58 - $212.00

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

-19.8x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $17.7 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $16.1 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. -16.2%
52-Week High Highest share price in the last 52 weeks. $212.00
52-Week Low Lowest share price in the last 52 weeks. $117.58
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.72
Outstanding Shares The number of shares the company has issued and are held by stockholders. 121 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 880 Thousand

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. -19.8
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -99.0
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. -$7.49
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 21.07
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 49.17
Enterprise Value to Revenue Enterprise value divided by revenue 18.31
Enterprise Value to EBIT Enterprise Value divided by EBIT -24.08
Total Debt to Enterprise Value Total debt divided by enterprise value 0.04
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 1.69

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $880 Million
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $735 Million
EBIT Earnings before tax and interest payments. -$669 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. -$893 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -101.47%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +20.0%
Return on Equity Equity divided by market cap. -222.57%
Return on Assets Indicates a company's profitability in relation to its total assets. -26.0%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. -23.66%

Insider trades

No purchases

No sells

No purchases

144.0 shares sold (1 transactions)

No purchases

30,000.0 shares sold (1 transactions)

No purchases

No sells

Q3 2021 Q4 2021 Q1 2022 Q2 2022

About Alnylam Pharmaceuticals Inc

CEO: John Maraganore

Industry: Pharmaceutical Preparation Manufacturing

Similar stocks

Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Sarepta Therapeutics Inc
Sarepta Therapeutics Inc
Opko Health Inc
Opko Health Inc
Novartis AG - ADR
Novartis AG - ADR
Sanofi - ADR
Sanofi - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
Teva- Pharmaceutical Industries Ltd. - ADR

News

Alnylam RNAi therapy for rare protein disorder gets FDA approval

Alnylam RNAi therapy for rare protein disorder gets FDA approval

The U.S. Food and Drug Administration ((FDA)) approved Alnylam (ALNY) Pharmaceuticals'' RNAi therapy Amvuttra (vutrisiran) to treat polyneuropathy of heredit...

Seeking Alpha Seeking Alpha, 12 days ago
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food an...

Business Wire Business Wire, 12 days ago
Alnylam says kidney disease therapy led to 37% drop in key indicator

Alnylam says kidney disease therapy led to 37% drop in key indicator

Alnylam Pharmaceuticals (ALNY), a biotech focused on RNA interference announced Thursday that its experimental RNAi therapy cemdisiran caused a 37% mean redu...

Seeking Alpha Seeking Alpha, 17 days ago
William Blair initiates Alnylam Pharmaceuticals with outperform rating

William Blair initiates Alnylam Pharmaceuticals with outperform rating

Brokerage William Blair on Tuesday initiated an outperform rating on Alnylam Pharmaceuticals (ALNY) stock, while estimating a fair value for the shares of $1...

Seeking Alpha Seeking Alpha, 18 days ago
Never miss a trade
To improve your user experience we use cookies.